Gensight Biologics (STU:G49N) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:G49N Gensight Biologics SA STU:G49N
7 GF Score
Price €0.12
GF Value €0.04
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Gensight Biologics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:G49N
7GF Score
Gensight Biologics SA STU:G49N
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gensight Biologics (STU:G49N) Overvalued in 2026?

Based on GuruFocus' analysis, Gensight Biologics stock appears to be overvalued. The current stock price of €0.12 is trading 193.5% above its estimated GF Value™ of €0.04. GuruFocus considers Gensight Biologics to be Significantly Overvalued.

Key valuation signals for STU:G49N:

  • Short Ratio:
  • GF Value™: €0.04 vs. price of €0.12 (193.5% above fair value)
  • GF Score™: 7/100 with 8 warning signs

No single metric tells the full story. See the STU:G49N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
7GF Score

Get the complete analysis for STU:G49N

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.04
GF Value